drugset / Trial / NCT04412889
A Study of BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM
NaSingle-groupOpen-labelTreatment
Summary
The study is an early, open, single-centered trial. The aim of this study is to evaluate the safety and tolerance of BCMA/CD19 dual-target CAR-T cell immunotherapy in relapsed or refractory MM. The study will include 18 subjects to receive BCMA/CD19 dual-target CAR-T cell immunotherapy.
Timeline
- Start
- 2020-06
- Primary completion
- 2022-12
- Completion
- 2022-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA/CD19 dual-target CAR-T cell immunotherapy | Cell therapy | 200000 cells/kg | — |
| Subject | BCMA/CD19 dual-target CAR-T cell immunotherapy | Cell therapy | 1e+06 cells/kg | — |